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ypertrophy: A “Factor of Risk”
ass Is Reversible, but Is the Risk?*
dward D. Frohlich, MD, FACC
ew Orleans, Louisiana
eft ventricular hypertrophy (LVH), specifically as it relates
o systemic arterial hypertension, is a major risk factor
nderlying coronary heart disease (CHD). The reduction of
entricular mass has not yet been demonstrated to amelio-
ate that risk, even though several reports have attested to
he fact that left ventricular (LV) mass is reduced by drugs.
his commentary concerns the subject of two papers pub-
ished in this issue of the Journal (1,2) that address this
opic.
See pages 2200 and 2207
The importance of LVH was stimulated by the Framing-
am Heart Study demonstration, which showed that it was
ne of three major “factors of risk” underlying CHD (3).
hereafter, investigative effort focused on the pathophysio-
ogic development of LVH. The study (4) soon reported
hat hypertension was the most common cause of cardiac
ailure, undoubtedly due to systolic dysfunction because
ntihypertensive therapy has not been available long
nough. However, despite its subsequent use, hypertension
as remained the major cause of cardiac failure, although
iastolic dysfunction also was postulated to be operative (5).
Soon after the earlier Framingham report, our laboratory,
sing roentgenographic and electrocardiographic (ECG)
riteria of LVH, demonstrated clinical progression from no
vidence of hypertensive heart disease (HHD) to its earliest
CG manifestation of left atrial (LA) abnormality and then
o clearly identifiable LVH (6). The LA abnormality was
ighly concordant with the fourth heart sound, higher
rterial pressure, and greater prevalence of cardiac dysrhyth-
ias. With the adaptation of echocardiography for HHD,
hese findings were extended in the first echocardiographic
HD study demonstrating that patients with an LA
bnormality already had increased LV mass as well as
reater septal and posterior wall thicknesses, although their
CGs did not yet demonstrate LVH (7). Furthermore, LV
jection fraction also was relatively reduced in patients with
n LA abnormality, decreasing further in patients with
CG-LVH (7). Soon, clinical interest in hypertensive
VH became stimulated further, and the Framingham
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.cFrom the Ochsner Clinic Foundation, New Orleans, Louisiana.roup confirmed their earlier ECG-LVH observation using
chocardiography as a means for earlier identification of
VH risk (8). Attention soon focused on the potential of
ntihypertensive therapy to “reverse” LVH (9).
It is inappropriate to consider herein that the clinical
orrelates responsible for the development or reversal of
VH are not pathophysiologically homogeneous, involving
spectrum of diseases and an increasing number of hu-
oral, endocrine, growth, and other factors. Because hy-
ertension is the most common disease producing LVH,
ne may not assume that LVH is only the result of
ypertension; it may occur with burned out myocardial
nfarction, ischemic or valvular heart diseases, aging, and so
orth, and may be promoted through similar biological
echanisms. Conversely, LVH may not be diminished
harmacologically through similar mechanisms. Initially,
ur experimental studies demonstrated that short-term
harmacologic treatment reduced LV mass (10), suggesting
hat nonhemodynamic as well as hemodynamic factors were
mportant in both LVH development and reversal (11,12).
hese reports clearly showed that rapid reduction in LV
ass was evident with all classes of antihypertensive agents
xcept, perhaps, the smooth muscle vasodilators (10), al-
hough when vasodilators were administered for long
nough periods of time, LV mass diminished (13,14). Early
n, we demonstrated LV mass reduction by using an
ngiotensin-converting enzyme inhibitor (15). Subse-
uently, broad interest in this and other classes of antihy-
ertensive drugs focused on LVH reversal.
It is important to emphasize that the clinical reversal (i.e.,
regression”) of hypertensive LVH does not necessarily
ean reduced risk, pari passu. Although the clinical surro-
ates of LVH represent adaptive functional responses to
ressure overload, they do not demonstrate the fundamental
isk factors that are associated with LVH. Furthermore,
VH induced by exercise neither impaired systolic function
or diastolic function, although hypertension did (16). Most
mportant, ECG (or echocardiographic) demonstration of
herapeutic LV mass reduction provides no information
bout underlying risk mechanisms. Thus, even if LV mass
nd risk are diminished pharmacologically, it does not
ollow that the mass reduction was responsible for reduced
isk. Other pharmacological epi-phenomena often co-exist
17), including ischemia (18), ventricular and perivascular
brosis in extracellular matrix (19), apoptosis (20), and
hrombosis.
Ischemia associated with LVH occurs in pure HHD, but
t also occurs with co-existing atherosclerotic epicardial
oronary arterial disease. Hypertensive heart disease isch-
mia also results from increased myocardial oxygen demand,
oronary arteriolar constriction, and endothelial dysfunction
17).
Reversible fibrosis has been confirmed clinically by septal
iopsy of patients with pure HHD relating to alterations in
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June 16, 2004:2216–8 Editorial Commentther mechanisms (21–23). Apoptosis is not produced by
yocardial infarction but by programmed cellular death
ssociated with such biological mechanisms as the local
enin-angiotensin-aldosterone system in the heart and ves-
els. In fact, recent studies have demonstrated that more
poptotic cells in the hypertensive heart than the normal
eart (18) is reversed by angiotensin II receptor blockade
nd may explain the greater prevalence of cardiac failure in
HD (24).
Interest in demonstrating a “reversal of LVH” risk stems
rom obvious reasons. If decreasing elevated arterial pressure
r serum cholesterol levels reduce associated cardiovascular
isk, then the demonstration of reduced risk might be
xpected with LVH “reversal.” To be sure, reduction in LV
ass echocardiographically correlates with reduced cardiac
ass by postmortem examination (25), but reversed myo-
ytic hypertrophy was not demonstrated. Moreover, just
ecause ECG or echocardiographic evidence of LVH is
iminished, the reduction of associated LVH risk does not
ollow. The U.S. Food and Drug Administration followed
he same line of thinking: the demonstration of LVH
eversal is not accepted as an indication of drug efficacy.
ndeed, in 1991, I cautioned that even if ECG or echocar-
iographic LVH was reduced, it did not follow that actual
isk of LVH was similarly diminished (24). One must
stablish that the reduced LVH risk is independent of the
ontemporaneous fall in arterial pressure, antiarrhythmic
rug effects, improved ischemia, or other epi-phenomena
ssociated with treatment(s) (26). Thus, the challenge of
emonstrating reduced CHD risk by decreasing LVH is far
ore complex.
Several attempts to demonstrate the value of different
lasses of antihypertensive agents to reduce LV mass in-
olved meta-analysis, but, to my way of thinking, this
echnique is fraught with problems. For example, some
tudies that were used included patients of one gender, all
ges or only the elderly or young, or one racial or ethnic
roup. Finally, most patients who had been included were
reated with a variety of drugs over varying time periods
ven though they may have been discontinued before the
ited studies (27). Recent work suggests that previous
herapy may promote myocytic “memory” from previous
ellular stimulation (28). Hence, these efforts provided little
o satisfy the need for new knowledge acquisition other than
o add further confusion to an already extremely complex
roblem.
But what about previous large clinical trials that might
ave added to our understanding concerning whether LVH
eduction reduced risk? One very early trial was conducted
uring the initial years of antihypertensive therapy by the
eterans Administration Cooperative Study Group. It
emonstrated a significant reduction in cardiac failure in the
atients who received active drug treatment in contrast to
lacebo (29). A very recent trial that was designed to
etermine the reduction of LVH risk demonstrated that
VH and arterial pressure were reduced by both study drugs hatenolol and losartan) (30), but only the angiotensin II
type 1) receptor antagonist demonstrated reduced risk from
troke and end-stage renal disease; however, risk reduction
rom LVH was not demonstrated. During the intervening
our decades, little was gleaned from the numerous trials
nvolving many other antihypertensive agents to demon-
trate LVH risk reduction, although all of the trials con-
rmed the absolute necessity for reduction and control of
ressure. However, these studies were neither designed to
emonstrate LVH risk reduction nor were their primary (or
econdary) end points.
This brings us to the two important reports published in
his issue of the Journal (1,2). The first, by Drazner et al. (1),
s a prospective multicenter trial from the Cardiovascular
ealth Study, demonstrating that increased LV mass was a
isk factor for the subsequent development of depressed LV
jection fraction within five years. The second, by Lonn et
l. (2), is a substudy from the Heart Outcomes Prevention
valuation study, demonstrating that the angiotensin-
onverting enzyme inhibitor ramipril was effective (10-mg
ose) in preserving LV ejection fraction associated with
educed LV mass and function in normotensive high-risk
ardiovascular patients.
The Cardiovascular Health Study is a prospective
opulation-based longitudinal study in which 3,042 partic-
pants were enrolled and followed for 4.9 years (1). All
atients had normal baseline LV ejection fraction and mass
ollowed with two-dimensional echocardiography. All pa-
ients were older than 65 years and were followed with a
ariety of cardiovascular measurements to determine devel-
pment of LVH and various other cardiovascular diseases.
hose patients with baseline echocardiograms having LV
ass greater than the median were no different from those
ith lesser measurements with respect to age, race, baseline
asting blood sugars, and history of diabetes. However, they
ncluded more male patients who were hypertensive and
ho received antihypertensive therapy. They weighed more,
ad a greater body mass index, had higher serum insulin
oncentrations, and had a greater amount of subsequent
trial fibrillation, Q waves, LVH, LV mass, and other LV
imensions within the five-year period. Moreover, in their
verall follow-up, there were more cardiovascular events
including myocardial infarction, heart failure) and, as
mphasized in the overall message of the report, developed
mpaired depressed LV function. The second report, a
ubstudy of the Heart Outcomes Prevention Evaluation
tudy, demonstrated that high-dose ramipril provided sig-
ificantly more beneficial effects on LV structure and
unction with preserved LV ejection fraction in these
lacebo-controlled high-risk vascular patients (2).
In summary, the prognosis with these two groups of older
atients at higher risk of subsequent cardiovascular events,
rovide encouraging findings that leave open the question of
he specific risk of LVH and the issue of LVH risk reversal.
e know that patients who were included with controlled
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Editorial Comment June 16, 2004:2216–8ocal cardiac renin-angiotensin system, diminished LV
ass, improved LV systolic function, and prevented remod-
ling and other adverse events. However, there were no
ositive therapeutic controls. Moreover, little is known
bout the underlying pathophysiologic events and the vari-
us diseases associated with LVH that predispose the
atients to increased risk. We must conclude that control of
rterial pressure in the hypertensive patients, preferably with
n angiotensin-converting enzyme inhibitor, should result
n improved cardiovascular outcomes. However, until pa-
ients with hypertension are prospectively followed with
ppropriately positive controls that exclude other potential
onfounding effects cited previously, the true natural history
ompared with other therapy must remain a subject of
onjecture.
eprint requests and correspondence: Dr. Edward D. Frohlich,
lton Ochsner Distinguished Scientist, Ochsner Clinic Founda-
ion, 1516 Jefferson Highway, New Orleans, Louisiana 70121.
-mail: efrohlich@ochsner.org.
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